Potent inhibitor of hcv serine protease
CA 2500259 A1 · Owner: Boehringer Ingelheim International Gmbh · Inventors: Croenlein, Jens Oliver; Chen, Shirlynn; Steinmann, Gerhard G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are oral pharmaceutical compositions kits and methods of treating , and preventing Hepatitis C Viral (HCV) infections wherein Compound (1) a , potent inhibitor of HCV serine protease or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range: Formula (1) Also disclosed are the use of a compound of formula (1) or a pharmaceutically , acceptable salt thereof as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances alone or in combination, to inhibit , the replication of HCV.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 25, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.